Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 50 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
AM.perfusion from Faimes, company number BE0771319749, closed financial year 2025 with a result of € -27,039 after tax. For that financial year AM.perfusion recorded a gross margin of € 47,285 and equity of € -23,525. Compared with financial year 2024, the result moved from € 12,934 to € -27,039. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2026.
€ -23,525
▼ € 27,039 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -27,039
▼ still € 12,934 profit in 2024
Profit after tax over the fiscal year.
€ 58,439
▼ 19% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -25,525.
People and assets in 2025
€ 56,605
▼ 26% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 47,137
▼ 25% vs 2024
€ 16,063 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 1,921
▲ € 1,813 vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 34,458 | € 51,539 | € 62,824 | € 47,285 | ▼ 25% |
| Profit after taxes | € 13,466 | € 25,234 | € 12,934 | € -27,039 | ▼ € 39,972 |
| Equity | € 25,345 | € 50,580 | € 3,513 | € -23,525 | ▼ € 27,039 |
| Total debts | € 86,354 | € 88,291 | € 164,635 | € 156,979 | ▼ 5% |
| Cash | - | € 77,484 | € 72,289 | € 58,439 | ▼ 19% |
| Retained profit | € 23,345 | € 48,580 | € 1,513 | € -25,525 | ▼ € 27,039 |
| Dividend | € 0 | € 0 | € 60,000 | € 0 | ▼ 100% |
| Bank debt | € 62,394 | € 47,931 | € 62,825 | € 47,137 | ▼ 25% |
| Balance sheet total | € 111,699 | € 138,870 | € 168,149 | € 133,454 | ▼ 21% |
Key figures of AM.perfusion, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to AM.perfusion?
What happened at AM.perfusion in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 27,039 (▼ € 39,972 vs 2024). filed late Source: NBB ↗
- New establishment in Faimes. KBO
- Laura Raniolo became a director. NBB
- Anthony Massaro became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 13,466 profit in 2022 to € 27,039 loss in 2025.
Paid € 22,857 in corporate taxes since 2022.
Best year ever: 2023, with € 25,234 profit.
Paid out € 60,000 in dividends to the owners in total.
Management
Behind AM.perfusion are Laura Raniolo and Anthony Massaro.
Directors
According to the 2025 annual accounts
Laura Raniolo
Director
since 2021
Anthony Massaro
Director
since 2021
Establishments
Establishment units
Physical locations of this company
Rue de Termogne 5
4317 Faimes
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
O2SWITCH, FR
Website info
Features
Security
Details
- Company number
- 0771.319.749
- VAT number
- BE 0771.319.749
- Registered office
- Rue de Termogne 5, 4317 Faimes
- Names & denominations
- AM.perfusion
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 13 July 2021
- Peppol
- Active · Active since 24 Nov 2025
- Contact
- srmd-hesbaye.be